Navigation Links
Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
Date:3/12/2008

tion of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assump
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
2. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
4. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
5. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
6. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
7. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
8. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
9. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
10. DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement
11. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  Synthetic Biologics, Inc. (NYSE MKT: ... drug candidates targeting specific pathogens that cause serious ... its final preclinical toxicology study of SYN-004. Per ... bridging study was required to move the Company,s ... the devastating effects of Clostridium difficile (C. ...
(Date:9/2/2014)... 2, 2014 Culot brings life ... lab management services  BioData, producer of Labguru, ... to announce the appointment of Louis Culot ... as VP Marketing and Business Development at BioDiscovery Inc., ... clinical applications. Previously, Culot worked for 17 ...
(Date:9/1/2014)... The Collaborative R&D Terms and ... comprehensive understanding and unprecedented access to the collaborative ... worlds leading life science companies. , The report ... and why companies enter collaborative R&D deals. , ... deals terms provides critical insight into the negotiation ...
(Date:8/31/2014)... August 31, 2014 This is ... state of the Epoxy Hardener industry in ... overview of the industry, including definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
Breaking Biology Technology:Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3
... MEDdevice Acquisition Co., LLC,MDAC is proud to announce that ... experience and proven success optimizing investments in,the medical device ... announced include:, Tony Dimun, CEO of Nascent Enterprises, ... Larry Gold, PhD, Chairman and CEO of SomaLogic ...
... May 14 Biodel Inc. (Nasdaq:,BIOD) today announced that ... and Treasurer of Biodel, will present a,corporate update at ... May 22, 2008 at 1:00 p.m. Eastern Time. The,conference ... New York, New York., Interested parties may access ...
... Company employees in nearly 50 nations are rolling up ... celebration of Lilly,s,first-ever Global Day of Service, possibly the ... day., Beginning at sunrise in New Zealand, Lilly ... energy to improve the health and,well-being of communities around ...
Cached Biology Technology:MEDdevice Acquisition Co., LLC Announces Board Members and Advisors 2Lilly Employees from Nearly 50 Nations Participate in Company's First-Ever Global Day of Service 2
(Date:8/29/2014)... some surprising discoveries about the body,s initial responses ... the team found that specialized cells in the ... viral invasion and are the source of gut ... (IL-1β). , Though aimed at the presence ... epithelium that provides a barrier to protect the ...
(Date:8/29/2014)... over the last 120,000 years may have influenced ... researchers led by City College of New York ... metric called "phylogeographic endemism." , It quantifies the ... is restricted in geographical space. , Dr. Carnaval, ... researchers from institutions in Brazil, Australia and the ...
(Date:8/29/2014)... prolific bloomer Emiliania huxleyi , can grow without ... contradicts the common view that E. huxleyi ... of thiamine in the ocean to survive. , "It,s ... says CIFAR Senior Fellow Alexandra Worden , co-author ... fellows John Archibald (Dalhousie University), Adrin ...
Breaking Biology News(10 mins):The early cost of HIV 2CCNY team defines new biodiversity metric 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... Fingerprinting for Kids" event on April 18 at ... CHESAPEAKE, Va., April 2 Turner Network Sales ... System, Inc. (TBS, Inc.), and truTV, are partnering with Cox ... "Digital Fingerprinting for Kids" event , a service designed ...
... Wins Gold Innovation Award; Senior Scientist Dr. Caleb ... Receives Certificate of RecognitionBOSTON, April 6 ... revolutionary biometric media research firm specializing in Emotional ... Awards from the Advertising Research Foundation.The Innovation Awards, ...
... Aware, Inc. (Nasdaq: AWRE ), a ... announced the preliminary results of its modified Dutch Auction ... City time, on Friday, April 17, 2009.In accordance with ... based on the preliminary count by Computershare Trust Company, ...
Cached Biology News:truTV and Cox Offer Free Digital Fingerprinting to Help Prevent Crimes Against Children 2truTV and Cox Offer Free Digital Fingerprinting to Help Prevent Crimes Against Children 3Innerscope Research(R) Receives Three Great Minds Innovation Awards from the Advertising Research Foundation 2Aware, Inc. Announces Preliminary Results of Dutch Auction Tender Offer 2Aware, Inc. Announces Preliminary Results of Dutch Auction Tender Offer 3
... (MUC3) is a glycoprotein. distributed in ... extent in breast, lung and salivary gland ... cross-reaction with MUC1 and MUC2. ... Immunogen: MUC3 tandem repeat peptide ...
... bottoms,• Nonreversible lids with ... contamination,• Individual alphanumerical codes ... footprint for ease in ... cell attachment,• Sterilized by ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Biology Products: